Khanh Hoang, MD
Cardiovascular Disease · McKinney, TXNPI 1609814912
Payments from drug & device makers
Across 136 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$397
- Pfizer$389
- Heartflow, Inc.$385
- Abbott$365
- Itamar Medical Inc$346
- Medtronic$228
- plus $2K from 30 others
What the payments were for
- Consulting fees$621%
- Food & beverage$4,05398%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $397 |
| Pfizer | 14 | $389 |
| Heartflow, Inc. | 5 | $385 |
| Abbott | 7 | $365 |
| Itamar Medical Inc | 4 | $346 |
| Medtronic(2 entities) | 9 | $228 |
| E.r. Squibb & Sons, L.L.C. | 14 | $220 |
| Boston Scientific | 5 | $199 |
| Novartis | 8 | $168 |
| Amgen | 8 | $153 |
| ZOLL Respicardia, Inc. | 1 | $122 |
| Abiomed | 4 | $118 |
| Kestra Medical Technology Services, Inc. | 4 | $115 |
| Bridgebio Pharma, Inc. | 3 | $84 |
| Merck | 4 | $79 |
| AstraZeneca | 5 | $77 |
| Atricure, Inc. | 1 | $73 |
| Boehringer Ingelheim | 4 | $70 |
| Cvrx, Inc. | 3 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Terumo Medical Corporation | 2 | $50 |
| Bard Peripheral Vascular, Inc. | 1 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Novo Nordisk | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Vital Connect, Inc | 1 | $19 |
| Recor Medical Inc | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$292
- WatchPATONE$257
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$168
- remede System$122
- VYNDAQEL$119
- Farapulse$109
- COREVALVE EVOLUT R$102
How this compares
$4,128 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 213 | $239,887 |
| EntrestoSacubitril/Valsartan | 63 | $58,111 |
| XareltoRivaroxaban | 40 | $25,518 |
| Repatha SureclickEvolocumab | 30 | $25,479 |
| JardianceEmpagliflozin | 19 | $18,546 |
| Praluent PenAlirocumab | 14 | $13,679 |
| FarxigaDapagliflozin Propanediol | 16 | $10,812 |
| Metoprolol Succinate | 292 | $4,862 |
| Rosuvastatin Calcium | 337 | $3,737 |
| Ranolazine ErRanolazine | 37 | $2,707 |
| Nebivolol Hcl | 25 | $2,317 |
| Losartan Potassium | 173 | $2,124 |
| Potassium Chloride | 107 | $1,713 |
| Carvedilol | 166 | $1,397 |
| Bumetanide | 32 | $1,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $389 | $239,887213 claims |
| NovartisEntresto | $168 | $58,11163 claims |
| Johnson & JohnsonXarelto | $12 | $25,51840 claims |
| Boehringer IngelheimJardiance | $70 | $18,54619 claims |
| AstraZenecaFarxiga | $77 | $10,81216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in McKinney
- Faisal WahidMcKinney$3.4M
- Wael Abo-AudaMcKinney$960K
- Muhammad KhanMcKinney$567K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.